Charles Swanton
Vermögen: 79 055 $ am 31.05.2026
Vermögen: 79 055 $ am 31.05.2026
Charles Swanton is the founder of Achilles Therapeutics Plc, founded in 2020, with no titles listed.
Dr. Swanton is the founder of Achilles Therapeutics UK Ltd., founded in 2016, with no titles listed.
Dr. Swanton is the founder of The Francis Crick Institute Ltd., founded in 2016, holding the title of Deputy Director-Clinical since 2023.
Dr. Swanton is also the founder of University College London.
Current jobs include Director at American Association for Cancer Research since 2019, Director at Bicycle Therapeutics Plc since 2025, and Director at Novartis AG starting in 2026.
Former jobs include Co-Director-Lung Cancer Centre of Excellence at Cancer Research UK and a position at UCL Medical School.
Education includes undergraduate studies at UCL Medical School and both undergraduate and doctorate degrees from University College London.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.04.2026 | 16’856 ( 0.04% ) | 79 055 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 12.08.2025 |
| NOVARTIS AG | Direktor/Vorstandsmitglied | 06.03.2026 |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Direktor/Vorstandsmitglied | 01.01.2019 |
The Francis Crick Institute Ltd.
The Francis Crick Institute Ltd. Investment Trusts/Mutual FundsMiscellaneous Operates as an independent charity that engages in biomedicine research | Gründer | - |
| Unternehmen | Position | Ende |
|---|---|---|
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Gründer | 01.01.2025 |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Gründer | - |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Provides cancer research services | Corporate Officer/Principal | - |
| ACHILLES THERAPEUTICS PLC | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Provides cancer research services | Commercial Services |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Commercial Services |
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops molecules and oncology medicines | Health Technology |
The Francis Crick Institute Ltd.
The Francis Crick Institute Ltd. Investment Trusts/Mutual FundsMiscellaneous Operates as an independent charity that engages in biomedicine research | Miscellaneous |
UCL Medical School
UCL Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Health Technology |
Achilles Therapeutics Plc
Achilles Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and sells cancer immunotherapies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen